Concepts (79)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Oncology Nursing | 4 | 2021 | 14 | 1.950 |
Why?
|
| Neoplasms | 5 | 2020 | 1238 | 1.300 |
Why?
|
| Antineoplastic Agents, Hormonal | 2 | 2019 | 30 | 1.230 |
Why?
|
| Antineoplastic Agents | 3 | 2018 | 632 | 0.990 |
Why?
|
| Competency-Based Education | 1 | 2024 | 28 | 0.910 |
Why?
|
| Education, Nursing, Graduate | 1 | 2024 | 49 | 0.860 |
Why?
|
| Advance Care Planning | 1 | 2021 | 61 | 0.690 |
Why?
|
| Curriculum | 1 | 2024 | 565 | 0.680 |
Why?
|
| Estrogen Receptor Modulators | 1 | 2019 | 7 | 0.650 |
Why?
|
| Aromatase Inhibitors | 1 | 2019 | 21 | 0.650 |
Why?
|
| Lutetium | 1 | 2018 | 2 | 0.610 |
Why?
|
| Neoplasm Metastasis | 1 | 2019 | 187 | 0.610 |
Why?
|
| Octreotide | 1 | 2018 | 4 | 0.610 |
Why?
|
| Somatostatin | 1 | 2018 | 19 | 0.610 |
Why?
|
| Intestinal Neoplasms | 1 | 2018 | 13 | 0.610 |
Why?
|
| Neuroendocrine Tumors | 1 | 2018 | 21 | 0.600 |
Why?
|
| Chemoprevention | 1 | 2018 | 39 | 0.590 |
Why?
|
| Stomach Neoplasms | 1 | 2018 | 69 | 0.580 |
Why?
|
| Radiopharmaceuticals | 1 | 2018 | 181 | 0.570 |
Why?
|
| Carcinogenesis | 1 | 2018 | 119 | 0.540 |
Why?
|
| Vulnerable Populations | 1 | 2017 | 84 | 0.520 |
Why?
|
| Genetic Testing | 1 | 2017 | 127 | 0.510 |
Why?
|
| DNA Damage | 1 | 2018 | 278 | 0.510 |
Why?
|
| Sepsis | 1 | 2020 | 278 | 0.510 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2015 | 19 | 0.490 |
Why?
|
| Pancreatic Neoplasms | 1 | 2018 | 332 | 0.480 |
Why?
|
| Nurse's Role | 1 | 2015 | 117 | 0.450 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2015 | 150 | 0.430 |
Why?
|
| Medication Adherence | 1 | 2015 | 243 | 0.410 |
Why?
|
| Health Promotion | 1 | 2017 | 471 | 0.410 |
Why?
|
| Drug Eruptions | 1 | 2011 | 14 | 0.370 |
Why?
|
| Patient Education as Topic | 1 | 2015 | 454 | 0.370 |
Why?
|
| Inflammation | 1 | 2018 | 1101 | 0.370 |
Why?
|
| Genomics | 1 | 2014 | 322 | 0.370 |
Why?
|
| ErbB Receptors | 1 | 2011 | 113 | 0.360 |
Why?
|
| Breast Neoplasms | 1 | 2019 | 1123 | 0.350 |
Why?
|
| Signal Transduction | 2 | 2018 | 2905 | 0.340 |
Why?
|
| Humans | 11 | 2024 | 59737 | 0.240 |
Why?
|
| Education, Nursing, Baccalaureate | 1 | 2024 | 38 | 0.220 |
Why?
|
| Students, Nursing | 1 | 2024 | 72 | 0.200 |
Why?
|
| Goals | 1 | 2021 | 88 | 0.170 |
Why?
|
| Symptom Assessment | 1 | 2020 | 44 | 0.160 |
Why?
|
| Health Services for the Aged | 1 | 2020 | 47 | 0.160 |
Why?
|
| Clinical Competence | 1 | 2024 | 688 | 0.160 |
Why?
|
| Palliative Care | 1 | 2021 | 217 | 0.150 |
Why?
|
| Nurse Practitioners | 1 | 2020 | 113 | 0.150 |
Why?
|
| Aged | 4 | 2020 | 13510 | 0.150 |
Why?
|
| Community Health Services | 1 | 2020 | 120 | 0.150 |
Why?
|
| Aged, 80 and over | 2 | 2018 | 5147 | 0.150 |
Why?
|
| Female | 5 | 2020 | 30925 | 0.140 |
Why?
|
| Caregivers | 1 | 2020 | 233 | 0.140 |
Why?
|
| Communication | 1 | 2021 | 547 | 0.130 |
Why?
|
| Adult | 3 | 2018 | 15771 | 0.130 |
Why?
|
| Middle Aged | 3 | 2018 | 16449 | 0.130 |
Why?
|
| Practice Guidelines as Topic | 1 | 2020 | 707 | 0.120 |
Why?
|
| Hospital Mortality | 1 | 2020 | 850 | 0.120 |
Why?
|
| Massachusetts | 2 | 2020 | 2027 | 0.120 |
Why?
|
| Nurse-Patient Relations | 1 | 2015 | 42 | 0.120 |
Why?
|
| Boston | 1 | 2015 | 249 | 0.110 |
Why?
|
| Administration, Oral | 1 | 2015 | 354 | 0.110 |
Why?
|
| Male | 4 | 2020 | 27952 | 0.110 |
Why?
|
| Registries | 1 | 2017 | 805 | 0.110 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2017 | 679 | 0.110 |
Why?
|
| Healthcare Disparities | 1 | 2017 | 330 | 0.100 |
Why?
|
| Feasibility Studies | 1 | 2015 | 531 | 0.100 |
Why?
|
| Risk Assessment | 1 | 2020 | 1935 | 0.100 |
Why?
|
| Child, Preschool | 1 | 2017 | 1802 | 0.100 |
Why?
|
| Pilot Projects | 1 | 2015 | 922 | 0.100 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2011 | 23 | 0.090 |
Why?
|
| Nursing Assessment | 1 | 2011 | 40 | 0.090 |
Why?
|
| Nursing Methodology Research | 1 | 2011 | 53 | 0.090 |
Why?
|
| Longitudinal Studies | 1 | 2015 | 1192 | 0.090 |
Why?
|
| Mutation | 1 | 2017 | 2462 | 0.080 |
Why?
|
| Retrospective Studies | 1 | 2020 | 6153 | 0.070 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2011 | 679 | 0.070 |
Why?
|
| Child | 1 | 2017 | 4215 | 0.070 |
Why?
|
| Surveys and Questionnaires | 1 | 2015 | 2520 | 0.070 |
Why?
|
| Young Adult | 1 | 2017 | 4290 | 0.070 |
Why?
|
| Adolescent | 1 | 2017 | 5866 | 0.070 |
Why?
|